TNFSF10 and chronic myelogenous leukemia, BCR-ABL1 positive: The findings suggested that both Dasatinib and TRAIL stimulate the programmed cell death of CML cells, but their combined use produced better therapeutic results, representing a new possibility for CML treatment.